Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial | Journal of Clinical Oncology
Vossloh North America | LinkedIn
Bedrijf uitgelicht- Skihut: “Veilig wintersporten wordt onderschat”
6th IAPC Meeting : : Book of Abstracts
Labor Day1
FEBRUARY 2011 PIN TITLE ADVANCEMENTS AMERICAS, EUROPE AND PACIFIC
Guide to STN Patent Databases – Basic Version - Paton - TU Ilmenau
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial | Journal of Clinical Oncology